Literature DB >> 10408492

Venous thromboembolism among new users of different oral contraceptives.

R M Herings, J Urquhart, H G Leufkens.   

Abstract

New use of third generation oral contraceptives is associated with a four-fold increased risk of venous thromboembolism compared with users of second generation oral contraceptives, particularly among young, healthy women.

Entities:  

Keywords:  Adolescents; Adolescents, Female; Age Factors; Biology; Cardiovascular Effects; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Demographic Factors; Desogestrel; Developed Countries; Diseases; Embolism; Ethinyl Estradiol; Europe; Family Planning; Netherlands; Oral Contraceptives; Physiology; Population; Population Characteristics; Research Report; Risk Factors; Thromboembolism; Vascular Diseases; Western Europe; Youth

Mesh：

Substances：

Year:  1999        PMID： 10408492     DOI： 10.1016/s0140-6736(99)01257-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  16 in total

1.  The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills.

Authors:  P A O'Brien
Journal:  BMJ       Date:  1999-09-25

2.  Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed.

Authors:  H Jick
Journal:  BMJ       Date:  2000-01-01

3.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

Authors:  J M Kemmeren; A Algra; D E Grobbee
Journal:  BMJ       Date:  2001-07-21

Review 4.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 5.  Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

Authors:  Lamberto Manzoli; Corrado De Vito; Carolina Marzuillo; Antonio Boccia; Paolo Villari
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

6.  Thrombophilia - how far and how much to investigate?

Authors:  R K Pinjala; L R C Reddy; R P Nihar; G V A Praveen; M Sandeep
Journal:  Indian J Surg       Date:  2012-01-13       Impact factor: 0.656

Review 7.  Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.

Authors:  A K Mantel-Teeuwisse; J M Kloosterman; A H Maitland-van der Zee; O H Klungel; A J Porsius; A de Boer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

8.  Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.

Authors:  H Jick; J A Kaye; C Vasilakis-Scaramozza; S S Jick
Journal:  BMJ       Date:  2000-11-11

9.  Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill.

Authors:  Maurizio Guida; Giuseppe Bifulco; Attilio Di Spiezio Sardo; Mariamaddalena Scala; Loredana Maria Sosa Fernandez; Carmine Nappi
Journal:  Int J Womens Health       Date:  2010-08-24

10.  Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use.

Authors:  Petr Dulicek; Eva Ivanova; Milan Kostal; Petr Sadilek; Martin Beranek; Pavel Zak; Jana Hirmerova
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.